BlossomHill Reports Positive Lung Cancer Trial Data, Boosting BLSM Outlook

Key Facts

1BH-30643 demonstrated a 45% objective response rate and an 88% disease control rate in NSCLC patients with resistance mutations.

2The drug recently received FDA Fast Track designation for the treatment of advanced or metastatic EGFR C797S-positive NSCLC.

In a move reflecting significant progress in the oncology biotech sector, BlossomHill Therapeutics has announced positive clinical data for its lead drug candidate. Results from the Phase 1/2 SOLARA trial of BH-30643 demonstrated a 45% objective response rate and an 88% disease control rate in NSCLC patients with resistance mutations. This announcement follows the drug's recent receipt of FDA Fast Track designation for treating advanced or metastatic cases.

This data is particularly significant as it targets a patient population with no currently approved targeted therapies, providing the company with a potential competitive edge. Per market data, BLSM shares closed at $21.74 on September 14, 2026, having reached a day high of $22.08. These levels reflect investor optimism following the data presentation at the IASLC 2026 World Conference on Lung Cancer, which also highlighted a favorable safety profile.

Looking ahead, traders are monitoring BLSM price levels following its recent trading range between $20.45 and $22.08 (as of close September 14, 2026). Key catalysts to watch include the company's plan to initiate a Phase 2 study in the first quarter of 2027. Regarding broader market drivers, there are no upcoming high-impact economic calendar events directly linked to the biotech sector in the immediate seven-day outlook.